A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Phase of Trial: Phase III
Latest Information Update: 01 Jul 2015
Price : $35 *
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms UNITY 2
- Sponsors Bristol-Myers Squibb
- 07 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Feb 2014 Planned End Date changed from 1 Dec 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 25 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History